During the past decade, Oddzial Chorob Wewnetrznych conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oddzial Chorob Wewnetrznych" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Oddzial Chorob Wewnetrznych" are "Diabetes Mellitus, Type 2" (2 trials). Many other conditions were trialed in "Oddzial Chorob Wewnetrznych" in a lesser frequency.

Most popular intervention types in "Oddzial Chorob Wewnetrznych" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Exenatide (AC2993)" (1 trials), "Insulin glargine" (1 trials), "Metformin" (1 trials), "Placebo" (1 trials) and "Sitagliptin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oddzial Chorob Wewnetrznych" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Oddzial Chorob Wewnetrznych". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Oddzial Chorob Wewnetrznych, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oddzial Chorob Wewnetrznych, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".